Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological and Histological Evaluation of rBet v1-FV Immunotherapy
NCT00841516Phase 2Completed
- Sponsor
- Allergopharma
- Start
- Dec 2007
- Primary completion
- Apr 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing Placebo with 80 µg rBet v1-FV (2 arms). Primary endpoint: Changes in populations of inflammatory cells and subpopulations of immunologically active cells at 1 year. Started Dec 2007; status: completed.
02
Drugs
rBet v1-FV
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00841516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00841516.